A consensus on criteria for cure of acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 7, 2010, Pages 3141-3148

  Giustina, Andrea ^a   Chanson, P ^b   Bronstein, M D ^c   Klibanski, A ^d   Lamberts, S ^e   Casanueva, F F ^f   Trainer, P ^g   Ghigo, E ^h   Ho, K ⁱ   Melmed, S ^j  

^a UNIVERSITY OF BRESCIA   (Italy)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^j CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GROWTH HORMONE; PEGVISOMANT; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR; HUMAN GROWTH HORMONE;

ACROMEGALY; ARTHRITIS; CANCER INHIBITION; CARDIOVASCULAR DISEASE; COMORBIDITY; CONFERENCE PAPER; CONSENSUS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DISEASE CONTROL; ENDOCRINOLOGY; HUMAN; HYPERTENSION; HYPOPHYSIS TUMOR; IMMUNOASSAY; MEASUREMENT ERROR; METABOLIC BONE DISEASE; MORTALITY; NEUROSURGERY; ORAL GLUCOSE TOLERANCE TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELIABILITY; SLEEP APNEA SYNDROME; STANDARD; SURGEON; TREATMENT OUTCOME; BLOOD; CONSENSUS DEVELOPMENT; METABOLISM;

ACROMEGALY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PRACTICE GUIDELINES AS TOPIC;

EID: 77954926018     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2670     Document Type: Conference Paper

References (98)

1. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A 2009 Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
2. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529 (Pubitemid 32273628)
3. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
4. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A 2005 Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737-740
5. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S 2003 Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242-1247
6. Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S 2008 Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31:820-838
7. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM 2008 Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:3266-3281
8. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso- Coello P, Schünemann HJ 2008 GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924-926 (Pubitemid 351632017)
9. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ 2007 Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 67:65-70 (Pubitemid 46955441)
10. Bidlingmaier M 2008 Problems with GH assays and strategies toward standardization. Eur J Endocrinol 159(Suppl 1):S41-S44
11. Arafat AM, Möhlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schöfl C, Pfeiffer AF 2008 Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 93:1254-1262 (Pubitemid 351519718)
12. Melmed S 2006 Medical progress: acromegaly. N Engl J Med 355: 2558-2573
13. Orme SM, McNally RJ, Cartwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730-2734
14. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM, Grossman AB 2001 Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 86:1645-1652 (Pubitemid 32374917)
15. Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G 2000 Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 85:4099-4103 (Pubitemid 32055359)
16. Massart C, Poirier JY 2006 Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays Clin Chim Acta 373:176-179
17. Trainer PJ, Barth J, Sturgeon C, Wieringaon G 2006 Consensus statement on the standardisation of GH assays. Eur J Endocrinol 155:1-2
18. Burns C, Rigsby P, Moore M, Rafferty B 2009 The First International Standard For Insulin-like Growth Factor-1 (IGF-1) for immunoassay: preparation and calibration in an international collaborative study. Growth Horm IGF Res 19:457-462
19. Sneppen SB, Lange M, Pedersen LM, Kristensen L LØ, Main KM, Juul A, Skakkebaek NE, Feldt-Rasmussen U 2001 Total and free insulin-like growth factor I, insulin-like growth factor binding protein 3 and acid-labile subunit reflect clinical activity in acromegaly. Growth Horm IGF Res 11:384-391 (Pubitemid 34428882)
20. Brabant G, von zur Mühlen A, Wüster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthén L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P 2003 Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 60:53-60
21. Minuto F, Resmini E, Boschetti M, Arvigo M, Sormani MP, Giusti M, Ferone D, Barreca A 2004 Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol (Oxf) 61:138-144 (Pubitemid 38951657)
22. Marzullo P, Di Somma C, Pratt KL, Khosravi J, Diamandis A, Lombardi G, Colao A, Rosenfeld RG 2001 Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 86:3001-3008 (Pubitemid 32673456)
23. Morrison KM, Bidlingmaier M, Stadler S, Wu Z, Skriver L, Strasburger CJ 2007 Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly. Eur J Endocrinol 156: 331-339 (Pubitemid 46554501)
24. Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A 2001 Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3. J Clin Endocrinol Metab 86:1091-1098 (Pubitemid 32322987)
25. Barkan AL, Dimaraki EV, Jessup SK, Symons KV, Ermolenko M, Jaffe CA 2003 Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. J Clin Endocrinol Metab 88:2180-2184 (Pubitemid 36549895)
26. Clemmons DR 2007 Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinol Metab Clin North Am 36:109-129
27. Juul A 2003 Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 13: 113-170 (Pubitemid 36986557)
28. Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797 (Pubitemid 128506521)
29. Carmichael JD, Bonert VS, Mirocha JM, Melmed S 2009 The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94:523-527
30. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171-1177 (Pubitemid 30211048)
31. Lau SL, McGrath S, Evain-Brion D, Smith R 2008 Clinical and biochemical improvement in acromegaly during pregnancy. J Endocrinol Invest 31:255-261 (Pubitemid 351638406)
32. Alexopoulou O, Bex M, Abs R, T'Sjoen G, Velkeniers B, Maiter D 2008 Divergence between growth hormone and insulin-like growth factor-1 concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93:1324-1330 (Pubitemid 351519728)
33. Cozzi R, Barausse M, Lodrini S, Lasio G, Attanasio R 2003 Estroprogestinic pill normalizes IGF-I levels in acromegalic women. J Endocrinol Invest 26:347-352 (Pubitemid 36763696)
34. Freda PU 2009 Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) 71:166-170
35. Ho KY, Weissberger AJ 1994 Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol (Oxf) 41:75-83 (Pubitemid 24232531)
36. Reutens AT, Veldhuis JD, Hoffman DM, Leung KC, Ho KK 1996 A highly sensitive growth hormone (GH) enzyme-linked immunosorbent assay uncovers increased contribution of a tonic mode of GH secretion in adults with organic GH deficiency. J Clin Endocrinol Metab 81:1591-1597
37. Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, Cappabianca P, Lombardi G 2006 Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol (Oxf) 65:250-256 (Pubitemid 44079691)
38. Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G 2005 Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf) 63:342-349 (Pubitemid 41233454)
39. Meinhardt UJ, Ho KK 2006 Modulation of growth hormone action by sex steroids. Clin Endocrinol (Oxf) 65:413-422 (Pubitemid 44414262)
40. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S 2004 Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 114:349-356 (Pubitemid 39071607)
41. Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM, Trainer PJ 2002 Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf) 57:59-64 (Pubitemid 34785884)
42. Vierhapper H, Heinze G, Gessl A, Exner M, Bieglmayr C 2003 Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 52:181-185 (Pubitemid 36388840)
43. van der Klaauw AA, Pereira AM, van Thiel SW, Frolich M, Iranmanesh A, Veldhuis JD, Roelfsema F, Romijn JA 2007 Attenuated pulse size, disorderly growth hormone and prolactin secretion with preserved nyctohemeral rhythm distinguish irradiated from surgically treated acromegaly patients. Clin Endocrinol (Oxf) 66:489-498 (Pubitemid 46434926)
44. Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K, Maiter D 2007 AcroBel the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 157:399-409
45. Puder JJ, Nilavar S, Post KD, Freda PU 2005 Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90:1972-1978 (Pubitemid 40590060)
46. Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW, van der Lely AJ, de Herder WW 2005 Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acidlabile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 90:6480-6489 (Pubitemid 41759303)
47. Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L 2009 Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94:2015-2022
48. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89: 1613-1617 (Pubitemid 38507910)
49. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP 2008 Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61-67
50. Holdaway IM, Bolland MJ, Gamble GD 2008 A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89-95
51. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
52. Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E, Pepe P, Falaschi F, Mariani G, Martino E 2007 Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271-4277 (Pubitemid 350080942)
53. Bogazzi F, Cosci C, Sardella C, Costa A, Manetti L, Gasperi M, Rossi G, Bartalena L, Martino E 2006 Identification of acromegalic patients at risk of developing colonic adenomas. J Clin Endocrinol Metab 91:1351-1356
54. Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A 2005 Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20:1837-1844 (Pubitemid 41361885)
55. Coculescu M, Niculescu D, Lichiardopol R, Purice M 2007 Insulin resistance and insulin secretion in non-diabetic acromegalic patients. Exp Clin Endocrinol Diabetes 115:308-316 (Pubitemid 46877864)
56. Nemes A, Gavallér H, Csajbók E, Julesz J, Forster T, Csanády M 2008 Aortic stiffness is increased in acromegaly: a transthoracic echocardiographic study. Int J Cardiol 124:121-123
57. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ 2004 Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 89:71-75
58. Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A, Pontecorvi A, DeMarinis L, Giustina A 2008 Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 93: 4649-4655
59. Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW 2003 Long-term treatment outcome in acromegaly. Growth Horm IGF Res 13:185-192
60. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95-102
61. Serri O, Beauregard C, Hardy J 2004 Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 89:658-661 (Pubitemid 38269873)
62. Grunstein RR, Ho KK, Sullivan CE 1994 Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 121:478-483
63. Davi MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia G 2008 Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 159:533-540
64. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ 2008 Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134:1570-1595 (Pubitemid 351615355)
65. Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, Matsuda T, Wu KC, Ng S, Leung SY, Makharia G, Chong VH, Ho KY, Brooks D, Lieberman DA, Chan FK 2008 Asia Pacific consensus recommendations for colorectal cancer screening. Gut 57:1166-1176
66. Van Cutsem EJ, Oliveira J 2008 Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 19(Suppl 2):ii29-ii30
67. Jenkins PJ, Fairclough PD 2002 Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut 51(Suppl 5): V13-V14
68. Beauregard C, Truong U, Hardy J, Serri O 2003 Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91 (Pubitemid 36098853)
69. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF 2003 Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88:3567-3572 (Pubitemid 37034496)
70. Ludecke DK, Abe T 2006 Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology 83:230-239 (Pubitemid 44578877)
71. Nomikos P, Buchfelder M, Fahlbusch R 2005 The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure.' Eur J Endocrinol 152:379-387
72. Shimon I, Cohen ZR, Ram Z, Hadani M 2001 Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 48:1239-1243; discussion 1244-1245
73. Attanasio R, Lanzi R, Losa M, Valentini F, Grimaldi F, De Menis E, Davì MV, Battista C, Castello R, Cremonini N, Razzore P, Rosato F, Montini M, Cozzi R 2008 Effects of lanreotide Autogel on growth hormone, insulin like growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 14:846-855
74. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G 2006 Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91:2112-2118
75. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G 2006 Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397-1403
76. Grottoli S, Celleno R, Gasco V, Pivonello R, Caramella D, Barreca A, Ragazzoni F, Pigliaru F, Alberti D, Ferrara R, Angeletti G 2005 Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study. J Endocrinol Invest 28:978-983
77. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P 2007 Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 67: 282-289
78. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A 2005 A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405-4410 (Pubitemid 41058228)
79. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J 2007 A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66:859-868 (Pubitemid 47024274)
80. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL 1998 Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034-3040
81. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Grasso LF, Lombardi G 2008 Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. J Clin Endocrinol Metab 93: 3436-3442
82. Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, Minuto F, Lombardi G, Pivonello R, Ferone D 2009 Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 71:237-245
83. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C 2002 Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65-71 (Pubitemid 34107323)
84. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A 2006 Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 29:86-93
85. Abe T, Lüdecke DK 2001 Effects of preoperative octreotide treat- ment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145:137-145 (Pubitemid 32707599)
86. Ben-Shlomo A, Melmed S 2003 Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 88:963-968 (Pubitemid 36337739)
87. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J 2008 Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93:2984-2990
88. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Calì A, de Divitiis E, Lombardi G 1997 Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308-3314 (Pubitemid 27419077)
89. Losa M, Mortini P, Urbaz L, Ribotto P, Castrignanó T, Giovanelli M 2006 Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 104:899-906
90. Plockinger U, Quabbe HJ 2005 Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien) 147:485-493; discussion 493
91. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A 2005 Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152:61-66 (Pubitemid 40185454)
92. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R 2006 Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91:85-92 (Pubitemid 43069122)
93. Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal- Sanderson V, Rowlers S, Trainer PJ, Wass JA 2008 Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 68:970-975
94. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD 2007 Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 67:310-315
95. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F 2004 Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89:2789-2796
96. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL 2002 Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87: 3537-3542
97. Freda PU, Post KD, Powell JS, Wardlaw SL 1998 Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 83:3808-3816
98. Espinosa-de-Los-Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G, Mendoza V, Hernandez I, Molina M, Mercado M 2006 Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin Endocrinol (Oxf) 64:245-249